Patent application number | Description | Published |
20140130134 | Managing and Providing Access to Applications in an Application-Store Module - According to one embodiment, a system includes an interface and a processor. The interface receives, from a device, a request to access an application-store module, the device being associated with a first user. The processor determines a device type associated with the device; determines an operating system associated with the device; determines a user role associated with the first user; and determines, based on the device type, the operating system, and the user role, one or more applications. The interface communicates, to the device, a first set of information to be displayed on the device, the first set of information being associated with the one or more applications. | 05-08-2014 |
20140143202 | Regulated Texting Solution for Mobile Devices - A system for consolidating data messages includes a memory that stores data messages. Each of the data messages has a user field, an outside party field, and a timestamp field. The first data message's user field is associated with a first user, the outside party field is associated with a first outside party, and the timestamp field is associated with a first timestamp. The third data message's user field is associated with a first user, the outside party field is associated with a first outside party, and the timestamp field is associated with a third timestamp. A processor then groups the first data message and the third data message based at least in part upon the user field, outside party field, and timestamp field of each message. The processor then combines the first data message and the third data message into a consolidated data message. | 05-22-2014 |
20140149998 | Interfacing Between Native and Web Applications Utilizing a Mobile Module - According to one embodiment of the present disclosure, interfacing between a plurality of applications for display on a mobile device includes receiving, by an interface, a request to open a plurality of applications. The plurality of applications are associated with a plurality of business units and comprise one or more native applications and one or more web applications. A processor opens the plurality of applications in a container according to a configuration file. The processor is communicatively coupled to the interface. The container is operable to be displayed on a user interface of the mobile device. | 05-29-2014 |
Patent application number | Description | Published |
20140129724 | END NETWORK DECIDER - According to one embodiment, an apparatus may store a mapping of a plurality of applications to a plurality of end networks. The apparatus may receive a request associated with executing an application from the plurality of applications and determine, based at least in part upon the mapping, an end network from the plurality of end networks that participates in the execution of the application. The end network may be mapped to the application. The apparatus may then establish a connection to the end network such that communications associated with the application are directed through the connection. | 05-08-2014 |
20140149906 | Electronic Bookshelf - According to one embodiment, one or more computer-readable non-transitory storage media may embody software that is operable, when executed, to present, on a display, a plurality of applications available for execution. The software may further receive a selection of an application from the plurality of applications and communicate a request associated with the application in response to receiving the selection. The software may then receive, in response to the request, the application in a packaged form. The packaged form may correspond to an operating system associated with the media. The software may also unpackage the application in order for the application to be executed and present, on the display, the results of executing the application. | 05-29-2014 |
Patent application number | Description | Published |
20090317470 | Oramucosal Pharmaceutical Dosage Form - This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation. | 12-24-2009 |
20100068169 | MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to an improved monolithic drug delivery dosage form which releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relax on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate. | 03-18-2010 |
20100179170 | HETEROGENEOUSLY CONFIGURED MULTIPARTICULATE GASTROINTESTINAL DRUG DELIVERY SYSTEM - This invention relates to a heterogeneously configured multiparticulate drug delivery system for gastrointestinal delivery of at least one or a combination of active pharmaceutical compositions. The system comprises a multiplicity of enterosoluble or gastrosoluble multiparticulates loaded with the active pharmaceutical composition or compositions for the site-specific delivery of said active pharmaceutical composition or compositions to a specific region in the gastrointestinal tract of a human or animal body. The system can be supplied as reconstitutable granules which are reconstituted immediately before oral administration. | 07-15-2010 |
20110182987 | PHARMACEUTICAL DOSAGE FORM FOR THE SITE-SPECIFIC DELIVERY OF MORE THAN ONE ACTIVE PHARMACEUTICAL INGREDIENT - This invention relates to a pharmaceutical dosage form for the site specific delivery of more than one active pharmaceutical ingredient to different sites in the human or animal body in the gastrointestinal tract. The dosage form has an outer polymeric layer incorporating a first active pharmaceutical ingredient which reacts to stimuli specific in the stomach, degrades, and releases the first active pharmaceutical ingredient in the stomach for absorption. The dosage form also has at least one inner polymeric layer incorporating a second active pharmaceutical ingredient which, once the outer layer has degraded, passes into the intestine where the polymers of the second layer degrade to release the second active pharmaceutical ingredient. The dosage form may have additional layers each incorporating active pharmaceutical ingredients for release in different portions of the intestine depending on the nature of the polymers. | 07-28-2011 |
20110182988 | GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM - This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract. | 07-28-2011 |
20120003316 | TRANSMUCOSAL DELIVERY SYSTEM - This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations. | 01-05-2012 |
20130252916 | ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM - This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation. | 09-26-2013 |
20150202153 | LIPOSOMAL DRUG DELIVERY SYSTEM - The invention relates to a drug delivery system, particularly to a liposomal drug delivery system. Most particularly the invention relates to a liposomal drug delivery system for the release of at least one drug compound at a target site within a human or animal body. The invention extends to a method of manufacturing the drug delivery system. | 07-23-2015 |
20150209275 | Fast Dissolving Ocular Insert - This invention relates to a pharmaceutical dosage form, particularly to a topical ocular pharmaceutical dosage form comprising a polymeric matrix of polyethylene oxide block copolymer, preferably polyoxyethylene-polyoxypropylene block copolymer and hydroxpropyl cellulose, and a pharmaceutically active ingredient incorporated within the matrix. The invention extends to a method of manufacturing the pharmaceutical dosage form. | 07-30-2015 |
Patent application number | Description | Published |
20110195116 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM - This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed. | 08-11-2011 |
20120064142 | POLYMERIC PHARMACEUTICAL DOSAGE FORM IN SUSTAINED RELEASE - This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers. | 03-15-2012 |
20130337022 | PHARMACEUTICAL DOSAGE FORM - A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent. | 12-19-2013 |
20130338569 | POLYMERIC HYDROGEL COMPOSITIONS WHICH RELEASE ACTIVE AGENTS IN RESPONSE TO ELECTRICAL STIMULUS - A polymeric hydrogel composition is described for the delivery of a pharmaceutically active agent when an electrical stimulus is applied to the composition. The composition comprises a polymer which forms the hydrogel, such as poly vinyl alcohol (PVA) cross-linked with diethyl acetamidomalonate (DAA), an electroactive polymer such as polyaniline and a pharmaceutically active agent such as an analgesic, and in particular, indomethacin. The composition can be subcutaneously implanted at a targeted site and under normal conditions, the active agent will be entrapped in the hydrogel itself. However, upon the application of an electric current to the hydrogel, the active agent will be released. When the electric current is removed, the change is reversed and the active agent will cease to be released. In one embodiment of the invention, the hydrogel composition is for use in alleviating chronic pain. | 12-19-2013 |
20130344125 | DRUG DELIVERY DEVICE - The invention provides an implantable intracranial device for the site-specific delivery of a pharmaceutically active agent to a human or animal for treating a mental or neurological disorder, such as Alzheimer's disease, schizophrenia or other psychoses. The biodegradable device includes a pharmaceutically active agent for treating the disorder, polymeric nano-lipoparticles into or onto which the pharmaceutically active agent is embedded; and a polymeric matrix or scaffold incorporating the nano-lipoparticles. The nano-lipoparticles can be in the form of nano-liposhells or nano-lipobubbles. The nano-liposhells or nano-lipobubbles can include an essential fatty acid or can be conjugated to a peptide ligand which targets the device to a specific cell into which the therapeutic agent can be delivered. The device can be implanted in the sub-arachnoid space in the region of the frontal lobe of the brain. | 12-26-2013 |
20140004185 | PHARMACEUTICAL COMPOSITION | 01-02-2014 |
20140005199 | IMPLANT FOR THE CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE AGENTS | 01-02-2014 |
20140005269 | POLYMERIC MATRIX OF POLYMER-LIPID NANOPARTICLES AS A PHARMACEUTICAL DOSAGE FORM | 01-02-2014 |
20140023692 | DRUG DELIVERY DEVICE - The invention provides an inflammation-responsive implantable device for the in situ delivery of one or more pharmaceutically active agents to a human or animal. The device comprises two differential release bioresponsive polymeric matrices (BPMs): an outer polymetric matrix and an inner polymeric matrix, both of which contain at least one pharmaceutically active agent or drug, typically an antibiotic and an anti-inflammatory agent, respectively. The therapeutically effective agent may be embedded in nanoparticles or nanobubbles. In response to inflammation, the pharmaceutically active agents are released, but at different rates: the rate of drug release from the inner polymeric matrix is lower than the rate of drug release from the outer polymeric matrix. Suitable polymers for forming the outer and inner polymeric matrices are hyaluronic acid and chitosan, respectively. A method of making the device and a method of treatment are also described. | 01-23-2014 |
Patent application number | Description | Published |
20100323007 | A POLYAMIDE RATE-MODULATED MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is selected for delivering, in use, the active compound, within a predetermined time frame depending on the biodegradable properties of the polymer, to a target organism or organisms. In one embodiment of the invention the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and, consequently, to control the release of the active compound. | 12-23-2010 |
20140037574 | PHARMACEUTICAL COMPOSITION - The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of CYP3A4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by CYP3A4. The inhibitor can be poly(ethylene glycol), methoxy poly(ethylene glycol), aminated poly(ethylene glycol), O-(2-aminoethyl)-O-methoxy poly(ethylene glycol), polyoxyethylene glycol, branched poly(ethylene glycol), 3-arm poly(ethylene glycol), 4-arm poly(ethylene glycol), 8-arm-poly(ethylene glycol)polyamine, poly(L-lysine), poly(L-arginine), poly(L-alanine), poly(L-valine), poly(L-serine), poly(L-histidine), poly(L-isoleucine), poly(L-leucine), poly(L-glutamic acid), poly(L-glutamine), poly(L-guanidine), poly(methyl methacrylate), polyvinyl acetate, polyacrylate, poly(lactic-co-glycolic acid) and derivatives thereof. A method of treatment is also described. | 02-06-2014 |